5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy-

Request For Quotation
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- Suppliers list
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- manufacturers

  • PHD2/HDACs-IN-1
  • PHD2/HDACs-IN-1 pictures
  • $2500.00
  • 2026-04-20
  • CAS:2339867-53-5
  • Purity:
  • Supply Ability: 10g
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- Basic information
Product Name:5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy-
Synonyms:5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy-;PHD2/HDACs-IN-1
CAS:2339867-53-5
MF:C18H19N9O4
MW:425.4
EINECS:
Product Categories:
Mol File:2339867-53-5.mol
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- Structure
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- Chemical Properties
density 1.68±0.1 g/cm3(Predicted)
pka5.72±0.50(Predicted)
Safety Information
MSDS Information
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- Usage And Synthesis
UsesPHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI)[1].
in vivo

PHD2/HDACs-IN-1 (10 mg/kg/day; i.p.; 2 days) has significant renal protecting effects on alleviating pathological injuries with considerably decreased tubular injury scores[1].

Animal Model:Male C57BL/6 mice (8 weeks; n=5) (Cisplatin-induced AKI)[1]
Dosage:10 mg/kg/day
Administration:i.p., 2 days
Result:Showed significant renal protecting effects on alleviating pathological injuries with considerably decreased tubular injury scores.
IC 50HDAC1: 19.75 μM (IC50); HDAC2: 26.60 μM (IC50); HDAC6: 15.98 μM (IC50); PHD2: 1.15 μM (IC50)
References[1] Wei H, et al. Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. Eur J Med Chem. 2022;230:114115. DOI:10.1016/j.ejmech.2022.114115
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- Preparation Products And Raw materials
Tag:5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy-(2339867-53-5) Related Product Information
5-Pyrimidinecarboxamide, 2-[4-[[[1,6-dihydro-6-oxo-2-(1H-pyrazol-1-yl)-5-pyrimidinyl]carbonyl]amino]-1-piperidinyl]-N-hydroxy- L-Phenylalanine, 4-[bis(2-chloroethyl)oxidoaMino]-, (Hydrochloride) (1:2) Carbamazepine Tucidinostat (Chidamide) 4-Phenylbutyric acid Chlorogenic acid